Genolution

Genolution EBITDA per Share

The EBITDA per Share of Genolution (225220.KQ) as of Oct 22, 2026 is -478.06 KRW. In the previous year, EBITDA per Share was -444.27 KRW — a change of 7.61% (lower).

EBITDA per Share

-478.06KRW

YoY

7.61%

Last updated:

EBITDA per Share of Genolution is 2025 -478.06 KRW. EBITDA per Share of Genolution was 2024 -444.27 KRW. It decreases by 7.61% lower compared to the previous year.

The Genolution EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
63.50 KRW
Jan 1, 2019
67.35 KRW
Jan 1, 2020
5,689.38 KRW
Jan 1, 2021
2,427.39 KRW
Jan 1, 2022
880.17 KRW
Jan 1, 2023
-391.60 KRW
Jan 1, 2024
-444.27 KRW
Jan 1, 2025
-478.06 KRW
The Genolution EBITDA per Share history
YEAREBITDA per ShareYoY
-478.06KRW+7.61%
-444.27KRW+13.45%
-391.60KRW-144.49%
880.17KRW-63.74%
2,427.39KRW-57.33%
5,689.38KRW+8,347.58%
67.35KRW+6.07%
63.50KRW-50.01%
127.01KRW+368.46%
27.11KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

EBITDA per Share of Genolution is -478.06 KRW in 2025.

EBITDA per Share of Genolution changed from -444.27 KRW to -478.06 KRW, representing a 7.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Genolution since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Genolution

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Genolution